We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinical Notes |

Hemolytic Anemia Secondary to Sali cylazosulfapyri dine Therapy

Morris D. Gardner, MD; J. Arnold Bargen, MD
JAMA. 1964;190(1):71-72. doi:10.1001/jama.1964.03070140077021.
Text Size: A A A
Published online


A PATIENT with chronic ulcerative colitis recently developed hemolytic anemia during treatment with salicylazosulfapyridine (Azulfidine). Although about 17% of the patients treated with this medication have mild side effects, serious reactions are seen rarely. This case is presented to bring the toxic potentialities of salicylazosulfapyridine therapy to the attention of the clinician.

Report of a Case  A 28-year-old civil engineer was admitted to Scott and White Memorial Hospital because of bright red rectal bleeding of one year's duration. The bleeding occurred with each daily bowel movement and the blood appeared on the surface of the feces. Occasionally, some mucus was observed; but, he did not have diarrhea, urgency, or abdominal cramping.The patient appeared healthy, was 6 feet, 5 inches tall (165.1 cm), and he weighed 179 pounds (81.2 kg). The only abnormal physical finding was that the lining of his rectum felt granular. The sigmoidoscopic examination revealed granular, friable


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.